Chromovert® improves discovery across all types of innovation

Cell-Based Drug Discovery

Creation of cells expressing disease genes for use to identity and develop new prospective drug candidates for clinical trials. We already have the human genome - Chromovert® has the demonstrated potential to action that data to make a drug for every gene.

Personalized Medicine

Making a drug for just one person or only one family was never more possible than now. Together with human genome data worldwide, our one-off drug discovery efforts add up to provide a growing arsenal of drugs for all of humankind.

READ MORE

Biologics & Vaccine Manufacturing

Creation of cell factories to produce protein, antibody and peptide drugs, along with creation of cells to produce immunogens to induce defensive vaccine responses and agents for gene therapy.

Biodefense and Pandemic Resiliency

Biodefense & Security: when speed counts, Chromovert® Technology saves time for vaccine and biologics production for accelerated biologics testing and production.

Cell & Stem Cell Therapies

Engineering of cells and stem cells to cure and treat disease. Now that we have the human genome, let's make a drug for every gene.

READ LESS

Cell engineering GPCRs:

The most common pathway to success

If you had to guess the target of a certain drug, your best odds are with “G-Protein Coupled Receptors (GPCRs)”. Drugs targeting members of this integral membrane protein superfamily, which transmit chemical signals into a wide array of different cell types, represent the core of modern medicine.

GPCRs account for the majority of best-selling drugs and about 50% of all prescription pharmaceuticals on the market. There is broad consensus that GPCRs will remain at the hub of drug development for the foreseeable future.

Today we start with GPCRs, tomorrow we find medicines for every disease gene in the Human Genome. Chromovert® Technology has been shown to improve and automate the drug discovery process. Next up, Drug Discovery at Scale.

~50%

of prescribed medicines target a member of the GPCR receptor family

GPCRs are among the most heavily investigated drug targets in the pharmaceutical industry

© 2024

Chromovert® Technology

These proteins are active in just about every organ and present a wide range of opportunities as therapeutic targets in areas including:

  • Cancer
  • Cardiac Dysfunction
  • Diabetes
  • Central Nervous System Disorders
  • Obesity
  • Inflammation
  • Pain
  • Aging

GPCRs are prominent components of all pharmaceutical and consumer pipelines, and many drug discovery firms focus exclusively on these receptors.

Despite multiple advances, including CRISPR, creating cells mimicking human biology remains a challenge.

The path to novel GPCR-targeted medicines is not routine. Most GPCR-modulating drugs on the market weren't initially targeted to a specific protein, but were developed on the basis of functional activity observed in an assay. That they activated or inhibited a GPCR specifically was only later discovered.

Post-Human Genome Project, however, GPCR targets are the starting points for most drug discovery endeavors. And there is still much to be learned about how GPCRs work and how they can be selectively modulated. Fortuitously, technologies designed specifically to tackle the GPCR challenge are blossoming.

What they said about us?

Almost always, building something is harder than tearing it down. Similarly, knocking in genes poses a greater challenge than knocking them out.

The Scientist

https://www.the-scientist.com

Until now, accessing GPCRs in their natural form as they exist in the body had been challenging

Chromovert® has been demonstrated to access dozens of previously out-of-reach GPCRs in their native and physiologically-relevant form (including heterodimeric GPCRs).

From GPCRs to every gene, our ultimate goal is to discover safer and more effective drugs to every known human gene

Want to learn more about Secondcell Bio ?

Get in touch with us